Newly, 3 new indications of the recombinant human vascular endothelial growth factor receptor-antibody fusion protein ophthalmic injection (HB002.1M) developed by Shanghai Huaota Biopharmaceutical Co., Ltd.’s subsidiary Huabo Biopharm(Shanghai) Co., Ltd. have been approved by the NMPA for clinical trial. Up to now, 4 indications of HB002.1M (age-related macular degeneration, branch retinal vein occlusion secondary to macular edema, central retinal vein occlusion secondary to macular edema and diabetic macular edema) have been approved for clinical study. The cooperation has invested a total of ￥87.60 million in research and development of HB002.1M. The first indication of HB002.1M (wet age-related macular degeneration) has progressed to phase II clinical trial. HB002.1M is a recombinant fusion protein targeting vascular endothelial growth factor (VEGF)，intended to treat the mentioned 4 indications. VEGF is recognized as the fastest and most effective vascular penetration and neovascularization inducing factor. The pathological processes of the 4 mentioned indications all associated with the abnormal expression of VEGF. Using recombinant proteins or monoclonal antibodies targeting VEGF can effectively treat the mentioned diseases.